source
- AbbVie reports 60% reduction in progression risk for myeloma drug etentamig in Phase 3 trialAbbVie announced results from a Phase 3 study of its T cell engager etentamig in patients with multiple myeloma. The trial demonstrated a 60% relative reduction in the risk of disease progression…
- Gene-edited pig kidneys enable patients to go months without dialysis before receiving human transplantsDoctors at eGenesis reported that two patients who received genetically engineered pig kidneys were later able to receive human donor kidneys after a period on dialysis. The transition was not seam…